Bloomage BioTechnology Corporation Limited

XSSC:688363 Stock Report

Market Cap: CN¥27.5b

Bloomage BioTechnology Valuation

Is 688363 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688363 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688363 (CN¥57.5) is trading above our estimate of fair value (CN¥12.15)

Significantly Below Fair Value: 688363 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688363?

Key metric: As 688363 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688363. This is calculated by dividing 688363's market cap by their current earnings.
What is 688363's PE Ratio?
PE Ratio62.5x
EarningsCN¥440.18m
Market CapCN¥27.51b

Price to Earnings Ratio vs Peers

How does 688363's PE Ratio compare to its peers?

The above table shows the PE ratio for 688363 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.6x
002007 Hualan Biological Engineering
22.8x18.7%CN¥30.5b
301301 Yili Chuanning BiotechnologyLtd
20.7x14.9%CN¥28.5b
603087 Gan & Lee Pharmaceuticals
46.1x43.2%CN¥26.8b
600161 Beijing Tiantan Biological Products
33x19.7%CN¥42.0b
688363 Bloomage BioTechnology
62.5x34.7%CN¥27.5b

Price-To-Earnings vs Peers: 688363 is expensive based on its Price-To-Earnings Ratio (62.5x) compared to the peer average (30.6x).

Price to Earnings Ratio vs Industry

How does 688363's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688363 62.5xIndustry Avg. 35.5xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688363 is expensive based on its Price-To-Earnings Ratio (62.5x) compared to the CN Biotechs industry average (37.3x).

Price to Earnings Ratio vs Fair Ratio

What is 688363's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688363 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.5x
Fair PE Ratio37.4x

Price-To-Earnings vs Fair Ratio: 688363 is expensive based on its Price-To-Earnings Ratio (62.5x) compared to the estimated Fair Price-To-Earnings Ratio (37.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688363 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥57.50
CN¥65.92
+14.6%
38.6%CN¥131.00CN¥40.00n/a9
Nov ’25CN¥60.00
CN¥65.26
+8.8%
39.2%CN¥131.00CN¥40.00n/a9
Oct ’25CN¥70.50
CN¥63.91
-9.4%
41.3%CN¥131.00CN¥40.00n/a9
Sep ’25CN¥50.30
CN¥63.91
+27.0%
41.3%CN¥131.00CN¥40.00n/a9
Aug ’25CN¥61.39
CN¥71.96
+17.2%
34.7%CN¥131.00CN¥45.00n/a9
Jul ’25CN¥56.22
CN¥71.96
+28.0%
34.7%CN¥131.00CN¥45.00n/a9
Jun ’25CN¥58.64
CN¥72.07
+22.9%
34.6%CN¥131.00CN¥45.00n/a9
May ’25CN¥61.50
CN¥75.39
+22.6%
35.0%CN¥131.00CN¥45.00n/a8
Apr ’25CN¥57.40
CN¥90.70
+58.0%
29.1%CN¥131.00CN¥55.00n/a9
Mar ’25CN¥63.51
CN¥92.89
+46.3%
26.8%CN¥131.00CN¥55.00n/a9
Feb ’25CN¥55.44
CN¥92.89
+67.6%
26.8%CN¥131.00CN¥55.00n/a9
Jan ’25CN¥66.93
CN¥95.11
+42.1%
23.3%CN¥131.00CN¥68.00n/a9
Dec ’24CN¥69.75
CN¥97.00
+39.1%
22.5%CN¥131.00CN¥68.00n/a10
Nov ’24CN¥75.43
CN¥104.43
+38.4%
21.4%CN¥137.71CN¥68.00CN¥60.0011
Oct ’24CN¥86.74
CN¥108.80
+25.4%
18.8%CN¥137.71CN¥70.00CN¥70.5011
Sep ’24CN¥92.87
CN¥107.50
+15.8%
20.4%CN¥137.71CN¥70.00CN¥50.309
Aug ’24CN¥95.18
CN¥115.43
+21.3%
19.3%CN¥150.00CN¥75.00CN¥61.3910
Jul ’24CN¥89.16
CN¥119.92
+34.5%
15.6%CN¥150.00CN¥95.00CN¥56.229
Jun ’24CN¥89.49
CN¥130.19
+45.5%
12.9%CN¥150.00CN¥98.00CN¥58.649
May ’24CN¥99.39
CN¥143.95
+44.8%
12.4%CN¥165.00CN¥98.00CN¥61.509
Apr ’24CN¥113.40
CN¥146.99
+29.6%
12.3%CN¥165.00CN¥100.00CN¥57.409
Mar ’24CN¥126.05
CN¥146.99
+16.6%
12.3%CN¥165.00CN¥100.00CN¥63.519
Feb ’24CN¥127.62
CN¥146.49
+14.8%
13.1%CN¥165.00CN¥100.00CN¥55.448
Jan ’24CN¥135.28
CN¥147.19
+8.8%
13.0%CN¥165.00CN¥100.00CN¥66.938
Dec ’23CN¥112.35
CN¥147.19
+31.0%
13.0%CN¥165.00CN¥100.00CN¥69.758
Nov ’23CN¥112.70
CN¥153.40
+36.1%
14.1%CN¥174.00CN¥100.00CN¥75.439

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%